SCHEMBL20529778

SCHEMBL20529778

CC=CN(C=CC)CC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
EYA2 O00167 1/20 0.38
APP P05067 1/20 0.38
ACE P12821 1/20 0.38
BLM P54132 2/20 0.36
PMP22 Q01453 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
CHRM2 P08172 1/20 0.36
ADRA2A P08913 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
DRD1 P21728 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
CYP2C19 P33261 1/20 0.36
ADRA1A P35348 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20529777 1.00 FFAR3 (0.38) FFAR3TDP1EYA2APPACE
SCHEMBL21076610 0.89 TDP1 (0.31) FFAR3TDP1EYA2APPACE
SCHEMBL15080934 0.86 TDP1 (0.32) TDP1EYA2APPACEBLM
SCHEMBL20529762 0.77 FFAR3 (0.43) FFAR3TDP1EYA2APPACE
SCHEMBL1976480 0.73 FFAR3 (0.39) FFAR3TDP1BLMLMNAALOX15
SCHEMBL1976479 0.73 FFAR3 (0.39) FFAR3TDP1BLMLMNAALOX15
SCHEMBL3829318 0.70 TDP1 (0.39) FFAR3TDP1EYA2APPACE
SCHEMBL20529760 0.70 F7 (0.52) TDP1BLMKDM4ELMNAALOX15
SCHEMBL8998478 0.69
SCHEMBL20529770 0.69 PPARG (0.55) TDP1BLMKDM4ELMNAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210324029-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY Bioniz Therapeutics, Inc. 2021-10-21 US claimed
EP-3606940-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY Bioniz, LLC (US) 2020-02-12 EP claimed
WO-2018187499-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY BIONIZ, LLC (US) 2018-10-11 WO claimed
US-20210324029-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY Bioniz Therapeutics, Inc. 2021-10-21 US disclosed
EP-3606940-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY Bioniz, LLC (US) 2020-02-12 EP disclosed
WO-2018187499-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY BIONIZ, LLC (US) 2018-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210324029-A1 STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY IL2, IL2RA, GMFG FFAR3 4567/4885TDP1 1486/4885EYA2 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.